NCT04888481RecruitingPhase 2
68Ga-HA-DOTATATE Imaging of Suspected Somatostatin Receptor Positive Tumors
Source: ClinicalTrials.gov · Last updated 11 May 2026
Brief summary (registry, in English)
Somatostatin receptor (SSR) imaging is a critical component of clinical care for many patients being investigated for or with confirmed SSR positive tumors. In the past, 111In-octreotide imaging has been used for this purpose but it has been recently supplanted globally by SSR positron emission tomography (PET) imaging due to better image quality and higher diagnostic accuracy. This study will assess the safety and diagnostic effectiveness of 68Ga-HA-DOTATATE produced a the Edmonton Radiopharmaceutical Centre (ERC).
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 600 (estimated)
- First submitted
- 12 May 2021
- Start date
- 15 Feb 2022
- Primary completion date
- 31 Aug 2027
- Lead sponsor
- University of Alberta
- Diseases
- Neuroendocrine tumours, Childhood cancers
- NCT number
- NCT04888481
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 600
- From 15 Feb 2022 to the primary completion date, 31 Aug 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous allergic reaction to DOTATATE or somatostatin analogues
Other illness
- Any additional medical condition, serious inter-current illness, or other extenuating circumstance that, in the opinion of the investigator or attending department physician, may significantly interfere with study performance or interpretation
Other
- Weight \> 225 kg (weight limit of the PET/CT scanner)
- Inability to scan (ie. extreme claustrophobia) or inability to lie still for imaging
- Lack of intravenous access
Who the study is looking for
- Patients with known or clinically suspected somatostatin receptor positive tumors including but not limited to: gastrointestinal neuroendocrine tumors, pancreatic neuroendocrine tumors, pulmonary neuroendocrine tumors, neuroendocrine tumors - primary unknown, pheochromocytoma, paraganglioma, medullary thyroid cancer, medulloblastoma, meningioma
- A standard clinical CT or MRI is obtained within 6 months of enrollment
- Ability to provide written informed consent prior to participation in the study (participant or if required a legal medical decision maker)
Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Alberta Coordinator of this site? Confirm its status | Edmonton | Canada | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.